Highlights•Protection from HCV persistence, not sterilizing immunity, is the goal of HCV
vaccine development.•An HCV vaccine eliciting T cells but not antibodies is in clinical testing …

The recent discovery of natural immunity to the hepatitis C virus and vaccine efficacy in the
chimpanzee challenge model has allowed optimism about the development of at least a …

Two chimpanzees, one naı̈ve (Ch1601) and one recovered from hepatitis C virus (HCV)
acute infection (Ch1587), were vaccinated with recombinant envelope glycoproteins (E1E2) …

The hepatitis C virus (HCV), first described in 1989, is now a leading cause of liver cirrhosis
and hepatocellular carcinoma. With more than 170 million people infected globally, this virus …

DNA-based immunization may be of prophylactic and therapeutic value for hepatitis C virus
(HCV) infection. In efforts to improve the immunogenicity of a plasmid expressing the second …

BACKGROUND: Hepatitis C virus (HCV) causes chronic liver disease that often leads to
cirrhosis and hepatocellular carcinoma. In animal studies, chimpanzees were protected …

Despite significant advances in the treatment of hepatitis C virus (HCV) infection, the need to
develop preventative vaccines remains. Identification of the best vaccine candidates and …

The development of vaccines that protect against persistent hepatitis C virus (HCV) infection
remain a public health priority. The broad use of highly effective direct-acting antivirals …

Hepatitis C virus (HCV) infects an estimated more than 150 million people and is a leading
cause of liver disease worldwide. The development of direct-acting antivirals (DAAs) will …

Approximately 4 million persons in the United States and probably more than 100 million
persons worldwide are infected with hepatitis C virus. The virus has the unique ability to …